Pharmaceutical developer Noxopharm has been awarded patent protection for its Veyonda treatment for late-stage cancers.
The patent, one of a number of families of patents the company is seeking in major drug markets, is for a suppository formulation including the drug idronoxil.
Idronoxil is an inhibitor of sphingosine-1-phosphate (S1P) – a messenger in cells that activates major pro-survival signalling pathways and regulates immune cell trafficking in tissues.
Research has shown that many solid cancers over-express S1P, with Noxopharm developing idronoxil to sensitise cancer cells to the anti-cancer effects of radiation and drugs such as doxorubicin.
Noxopharm CEO Graham Kelly said: “This news is an important step forward for the company and will go a long way to underpinning our proprietary ownership of Veyonda.
“(It has) considerable potential commercial value given the strength of the emerging clinical data.”
Noxopharm’s Veyonda has been designed to treat patients with late-stage, progressive and metastatic cancers that have limited survival prospects.
Noxopharm is also the major shareholder in Nyrada which is developing non-oncology drugs.
Subscribe to our free @AuManufacturing newsletter here.